Sol-Gel Technologies Ltd. (SLGL)
Stock Price:
$8.18 USD
-0.29 (-3.42%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
188.11M |
| Revenue (ttm) |
22.90M |
| Net Income (ttm) |
-24.61M |
| Shares Out |
23.00M |
| EPS (ttm) |
-1.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$8.18 |
| Previous Close |
$8.47 |
| Change ($) |
-0.29 |
| Change (%) |
-3.42% |
| Day's Open |
8.38 |
| Day's Range |
8.16 - 8.38 |
| Day's Volume |
8,109 |
| 52-Week Range |
5.00 - 21.00 |
More Stats
| Market Cap |
188.11M |
| Enterprise Value |
139.78M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
23.00M |
| Float |
8.48M |
| EPS (basic) |
-1.26 |
| EPS (diluted) |
-1.33 |
| FCF / Share |
-1.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
98,972 |
| Short Ratio |
7.38 |
| Short % of Float |
1.17% |
| Beta |
1.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
8.21 |
| PB Ratio |
2.88 |
| Revenue |
22.90M |
| Operating Income |
-25.95M |
| Net Income |
-24.61M |
| Free Cash Flow |
-23.10M |
| Net Cash |
48.33M |
| Net Cash / Share |
2.10 |
| Gross Margin |
-132.38% |
| Operating Margin |
-113.30% |
| Profit Margin |
-107.40% |
| FCF Margin |
-100.84% |
| ROA |
-26.55% |
| ROE |
-46.79% |
| ROIC |
-46.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.25*
(147.56% upside)
Low
16.0
Current: $8.18
High
23.0
Target: 20.25
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 22.90 | 0.13 | 0.17 | - | - |
| Revenue Growth | 17655.04% | -25.86% | - | - | - |
| Gross Profit | 22.90 | 0.13 | 0.17 | - | - |
| Operating Income | -25.95 | -33.52 | -31.63 | -20.76 | -9.65 |
| Net Income | -24.61 | -32.20 | -31.57 | -20.77 | -9.66 |
| Shares Outstanding | 19.53 | 17.87 | 6.29 | 6.29 | 6.29 |
| Earnings Per Share | -1.26 | -1.80 | -5.02 | -3.30 | -1.53 |
| Operating Cash Flow | -22.50 | -23.47 | -24.09 | -18.50 | -8.04 |
| Capital Expenditures | -0.60 | -1.05 | -1.93 | -0.39 | -0.29 |
| Free Cash Flow | -23.10 | -24.52 | -26.01 | -18.88 | -8.34 |
| Cash & Equivalents | 50.38 | 62.99 | 9.02 | 7.00 | 5.90 |
| Total Debt | 2.05 | - | 65.34 | 37.34 | 17.34 |
| Net Cash / Debt | 48.33 | 62.99 | -56.31 | -30.34 | -11.44 |
| Assets | 61.30 | 69.68 | 15.32 | 10.99 | 8.24 |
| Liabilities | 8.84 | 5.77 | 68.01 | 42.32 | 19.76 |
| Book Value | 52.47 | 63.91 | -52.70 | -31.34 | -11.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Sol-Gel Technologies Ltd. |
| Country |
Israel |
| Employees |
61 |
| CEO |
Alon Seri-Levy |
Stock Information
| Ticker Symbol |
SLGL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SLGL |
| IPO Date |
January 23, 2018 |
Description
Sol-Gel Technologies, a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatment of palmoplantar keratoderma and non-melanoma skin cancer; and tapinarof and roflumilast to treat psoriasis and other dermatological indications. It is also involved in the development of generic topical dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.